ObsEva (OBSV) sees the coverage initiated by BMO Capital with a price of $ 20



[ad_1]

<! –

News Stock

->

December 5, 2017 – By Michael Collier

   ObsEva (OBSV) sees coverage initiated by BMO Capital with a price of $ 20

Why BMO Capital has granted ObsEva (OBSV) a goal $ 20 price tag

The BMO Capital badyst initiated the hedge with a rating of "Outperform" at ObsEva (OBSV) today and set a target price of $ 20. The company shares were opened today at 0.

Rating coverage of ObsEva SA (NASDAQ: OBSV)

Among 6 badysts covering ObsEva (OBSV), 6 have Buy, 0 Sell and 0 Hold ratings. Therefore, 100% is positive. ObsEva has $ 27.0 higher and $ 16.0 lower goal. The average goal of $ 20.33 is 106.19% above the current $ 9.86 share price. ObsEva had 17 badyst reports from February 21, 2017 according to SRatingsIntel. The action of ObsEva SA (NASDAQ: OBSV) obtained the "Buy" rating by Jefferies on Tuesday, February 21. The rating was initiated by Credit Suisse on Tuesday, February 21 with "Outperform". H.C. Wainwright maintained the shares with a "Buy" rating in the report on Wednesday, November 8. H.C. Wainwright maintained the rating of ObsEva SA (NASDAQ: OBSV) on Friday, September 8. H.C. Wainwright has a "Buy" rating and a goal of $ 27.0. The rating was maintained by H.C. Wainwright with "Buy" on Wednesday, August 16. The action of ObsEva SA (NASDAQ: OBSV) has a "Purchase" rating granted on Thursday, September 14 by RBC Capital Markets. The company was started on Tuesday, February 21 by Leerink Swann. The rating was maintained by H.C. Wainwright on Monday, October 30 with "Buy". The firm was awarded the "Buy" rating on Wednesday, October 11 by H.C. Wainwright. The rating was maintained by RBC Capital Markets on Thursday, November 2 with "Buy".

The stock declined 2.57% or $ 0.26 during the last trading session, reaching $ 9.86. Around 13,443 shares traded. ObsEva SA (OBSV) has 0.00% since December 5, 2016 and it is. It has underperformed 16.70% of the S & P500.

ObsEva SA, a biopharmaceutical company in the clinical stage, focuses on the development and commercialization of new therapies for women suffering from reproductive health and pregnancy disorders. The company has a market capitalization of $ 366.12 million. The company intends to develop products for the treatment of endometriosis, uterine fibroids and premature labor, as well as to improve clinical pregnancy and live birth rates in women undergoing IVF. Currently he has negative earnings. He is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain badociated with endometriosis and heavy menstrual bleeding badociated with uterine fibroids in premenopausal women; Nolasiban, an oral oxytocin receptor antagonist to improve clinical pregnancy and live birth rates in women undergoing IVF; and OBE022, an oral and selective prostaglandin F2a receptor antagonist, as a once-a-day treatment for preterm labor in weeks 24 to 34 of pregnancy.

The most recent and notable news of ObsEva SA (NASDAQ: OBSV) was published by: Globenewswire.com published: "ObsEva SA announces the price of the initial public offering" on January 26, 2017, also Finance.Yahoo. com with your article: "ObsEva SA will attend LEERINK Partners Global Healthcare Conference in New York" published on February 3, 2017, Streetinsider. com published: "ObsEva SA (OBSV) starts PROLONG, the Phase 2A clinical trial of OBE022 in …" on December 05, 2017. More interesting news about ObsEva SA (NASDAQ: OBSV) was published by: Globenewswire.com and his article: "ObsEva SA announces the completion of a Phase 1 PK / PD clinical trial …" published on June 7, 2017, as well as the Globenewswire.com news article entitled: "ObsEva SA (Nasdaq: OBSV) will call the opening of the Nasdaq Bell in … stock market with publication date: January 26, 2017.

Receive news and ratings by email – Enter your email address below to Receive a concise daily summary of the latest news and badyst rankings with our FREE daily newsletter.


[ad_2]
Source link

Leave a Reply

Your email address will not be published.